Locust Walk Acquisition Corp.
Status: Deal Closed
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $175.00M |
|---|---|
| IPO Date | Jan 8, 2021 |
| CEO | Chris Ehrlich |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Healthcare in the United States and Europe |
| IPO Geography | Global |
| Target Company | eFFECTOR Therapeutics |
| Deal Announced | May 27, 2021 |
| Deal Size, $M | $419.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Aug 24, 2021 |
| Amendment Vote | TBD |
| Closing Date | Aug 25, 2021 |
Formerly LWAC
EFTR
EFTRW
| Price | $1.75 $0.07 |
|---|---|
| Last closing price | $1.78 |
| H/L, today | $1.60 / $1.80 |
| H/L, 52-week | $0.34 / $1.48 |
| Volume, today | 197,040 |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | $0.02 |
|---|---|
| Last closing price | $0.03 |
| High/low price, today | $0.02 / $0.03 |
| High/low price, 52-week | $0.06 / $0.27 |
| Volume, today | 30,124 |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Locust Walk Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 17 filings and events
- 1 underwriters
- 7 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Chris Ehrlich | 50 | Chief Executive Officer and Director |
| Daniel Geffken | 63 | Chief Financial Officer |
| Brian G. Atwood | 68 | Director |
| Elizabeth P. Bhatt | 53 | Director |
| Barbara A. Kosacz | 62 | Director |
| Caroline M. Loewy | 54 | Director |
| Ryan Gilbert | Advisor | |
| Shami Patel | Advisor |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Cantor Fitzgerald | BR | 15,300,000 | units |
| 15,300,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.
Filings
Sign in to view 17 filings.